Please login to the form below

Not currently logged in
Email:
Password:

Grifols

This page shows the latest Grifols news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic

FDA panel rejects Aradigm/Grifols’ inhaled antibiotic. Further evidence is required to warrant approval according to the US regulator. ... The setback is also a blow to Spanish drugmaker Grifols, which bought into the phase III programme for Linhaliq

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    2, 180. Hologic (US). Grifols (Spain). Asset acquisition. Nucleic Acid Testing (NAT) technology for R&D and manufacturing of assays and instruments for blood screening. ... The Gold award is won by Grifols, with a 13.6% rise in share price since the

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    1, 800. Novartis / Grifols. Acquisition. Novartis divestment of its blood transfusion testing unit.

  • Pharma deals during November 2013 Pharma deals during November 2013

    In the same vein, Novartis is reviewing its strategy and announced the divestment of its blood transfusion diagnostics unit for $1.7bn to Grifols as part of its ongoing business review.

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    220. Therasphere/ BTG. Asset purchase. Treatment for liver cancer. 200. Aradigm/ Grifols .

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics